Mindy Valcarcel is a copy editor for Healio, specializing in oncology news. With a keen eye for detail and a passion for accuracy, Mindy ensures that articles published on Healio are well-edited and adhere to the highest standards of journalism. Her contributions help to deliver up-to-date and reliable information to healthcare professionals and researchers in the field of oncology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mindy Valcarcel's coverage primarily focuses on healthcare, with a strong emphasis on citing data to support her articles. She frequently covers topics related to cancer treatment, pain management, and women in the medical profession.
Given Mindy's reliance on data-driven content, she would likely be receptive to pitches from experts and researchers who can provide insights backed by solid scientific or medical evidence. Additionally, professionals with firsthand experience in implementing innovative treatments or addressing challenges within the healthcare system may capture her interest.
As there is no specific geographic focus mentioned for Mindy's coverage, it appears that she takes a broad approach to healthcare topics without being confined to a particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mindy Valcarcel, David Statman
Video Player is loading. Play Video Play Mute Current Time Duration Loaded
By: Mindy Valcarcel, David Statman
In this video, Amy Dickey , MD MSc, discusses a study presented at ASH Annual Meeting that examined treatment of erythropoetic protoporphyria and X-linked protoporphyria.
By: Mindy Valcarcel, David Statman
In this video, Amy Dickey , MD MSc, discusses an educational session she presented at ASH Annual Meeting that examined the use of givosarin for patients with acute intermittent porphyria.
By: Mindy Valcarcel, David Statman
Video Player is loading. Play Video Play Mute Current Time Duration Loaded
By: Mindy Valcarcel, Paolo Caimi, Erin Michael
Video Player is loading. Play Video Play Mute Current Time Duration Loaded
By: Mindy Valcarcel, Paolo Caimi, Erin Michael
Video Player is loading. Play Video Play Mute Current Time Duration Loaded
By: Mindy Valcarcel, Jennifer R. Southall
Data showed a lower likelihood for women as first and last authors of oncology clinical trials in industry-sponsored and high impact journals, according to study results presented at ASH Annual Meeting and Exposition.
By: Marco Ruella, Mindy Valcarcel, Erin Michael
SAN DIEGO — A ketogenic diet may improve antitumor function through beta-hydroxybutyrate, according to early research presented in a plenary scientific session at the ASH Annual Meeting and Exposition.
By: Jennifer Byrne, Mindy Valcarcel
SAN DIEGO — Patients underrepresented in pivotal trials of anti-CD19 chimeric antigen receptor T-cell therapy may still derive benefit from the treatment modality, according to a speaker at ASH Annual Meeting and Exposition.
By: Matthew Shinkle, Mindy Valcarcel
SAN DIEGO — Tabelecleucel provided durable benefit to solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease, according to study results.
(833) 317-6278 
